- Home
- CLRB vs EKSO Comparison
CLRB vs EKSO Comparison
Compare CLRB & EKSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- EKSO
- Stock Information
- Founded
- CLRB 2002
- EKSO 2005
- Country
- CLRB United States
- EKSO United States
- Employees
- CLRB N/A
- EKSO N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- EKSO Medical/Dental Instruments
- Sector
- CLRB Health Care
- EKSO Health Care
- Exchange
- CLRB Nasdaq
- EKSO Nasdaq
- Market Cap
- CLRB 15.3M
- EKSO 13.4M
- IPO Year
- CLRB N/A
- EKSO N/A
- Fundamental
- Price
- CLRB $0.31
- EKSO $0.55
- Analyst Decision
- CLRB Buy
- EKSO Strong Buy
- Analyst Count
- CLRB 2
- EKSO 2
- Target Price
- CLRB $28.00
- EKSO $5.50
- AVG Volume (30 Days)
- CLRB 1.4M
- EKSO 318.5K
- Earning Date
- CLRB 03-26-2025
- EKSO 03-03-2025
- Dividend Yield
- CLRB N/A
- EKSO N/A
- EPS Growth
- CLRB N/A
- EKSO N/A
- EPS
- CLRB N/A
- EKSO N/A
- Revenue
- CLRB N/A
- EKSO $17,682,000.00
- Revenue This Year
- CLRB N/A
- EKSO N/A
- Revenue Next Year
- CLRB N/A
- EKSO $32.74
- P/E Ratio
- CLRB N/A
- EKSO N/A
- Revenue Growth
- CLRB N/A
- EKSO 4.12
- 52 Week Low
- CLRB $0.22
- EKSO $0.47
- 52 Week High
- CLRB $4.45
- EKSO $2.16
- Technical
- Relative Strength Index (RSI)
- CLRB 46.10
- EKSO 42.05
- Support Level
- CLRB $0.26
- EKSO $0.50
- Resistance Level
- CLRB $0.35
- EKSO $0.61
- Average True Range (ATR)
- CLRB 0.03
- EKSO 0.04
- MACD
- CLRB 0.02
- EKSO 0.00
- Stochastic Oscillator
- CLRB 61.40
- EKSO 57.33
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The regions company operates in are the Americas, EMEA, and APAC.